News from US Project NextGen:

The 3 vaccines from the USA chosen for Project NextGen are:

• Gritstone Bio’s self-amplifying mRNA vaccine aiming to be “variant-proof”;
• Covi-Vac/CoviLiv: A live virus intranasal vaccine from Codagenix; and
• Castlevax viral vector intranasal vaccine, from a Mount Sinai Hospital spin-off.

Mucosal vaccines:

• Mucosal vaccines are currently authorized for use in 6 countries: China, India, Indonesia, Iran, Morocco, and Russia. There are 5 of these vaccines: China has 2, and one of them is authorized in 3 countries:
  • Ad5-nCoV (Convidecia Air) Viral vector (adenovirus) vaccine by by CanSino (China)
  • BBV154 (iNCOVACC) Viral vector (adenovirus) intranasal vaccine by Bharat Biotech (India), using ChAd-SARS-CoV-2-S by Washington University in St Louis
  • DNS1-RBD (Pneucolin) viral vector intranasal vaccine, by Beijing Wantai BioPharm (China)
  • Razi Cov Pars Protein subunit by Razi Vaccine & Serum Research Institute (Iran)
• 27 have reached clinical trial, with at least one of those has been discontinued.
• 6 mucosal vaccines have reached phase 3 trials, including the 5 authorized vaccines.